News

Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today announced dosing of the first patient in its Phase 1/2 clinical trial of NRTX-1001 cell therapy in adults with drug-resistant bilateral mesial temporal...

Born in California and Innovator Awards 2025

University of California ventures were center stage at the 2025 Born in California event, held May 5 at the Cove at UC Irvine’s Beall Applied Innovation. The event brought together 20 startups from all 10 University of California campuses and drew more than 200 attendees, including investors,...

Montara Therapeutics to Develop Novel Treatments Using the BrainOnly™ Platform with Grant from The Michael J. Fox Foundation

Montara Therapeutics, a biotech company pioneering brain-selective therapies for central nervous system (CNS) diseases, today announced it has received a research grant from The Michael J.

BeeKeeperAI and cStructure Collaborate to Advance Causal AI for Scientific Advancement and Healthcare Innovation

BeeKeeperAI, a pioneer in privacy-enhancing, multi-party collaboration software for AI development and deployment, and cStructure, a leading innovator in collaborative causal inference, today announced a collaboration for advancing causal AI to speed up the ability of scientists, health data...

New Data Show Delve Bio’s Metagenomic Platform Accurately Identifies Viruses and Their Subtypes With a Single Test

Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data showing that its groundbreaking infectious disease test, Delve Detect, is also capable of viral subtyping for select pathogens from sequence data analyzed through its proprietary...

Phase 3 Study to Test 1st Generation Antihistamine EPX-100 in Lennox-Gastaut Syndrome

A new phase 3 study (NCT05066217) will test the efficacy and safety of EPX-100 (Harmony Biosciences), a 1st generation antihistamine agent, as a potential treatment for patients with Lennox-Gastaut syndrome (LGS), a rare epileptic disorder. Overall, the study will enroll patients aged at least 2...

Stephen Hauser Wins Breakthrough Prize for Role in Redefining MS

UCSF Luminary has played a pivotal part in identifying the cause of multiple sclerosis, leading to a new generation of game-changing therapies. 

Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline

 Neurona Therapeutics, a clinical-stage, privately-held, biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, today announced the successful completion of an upsized and oversubscribed $102 million financing.

Enhanced Brain Implant Translates Stroke Survivor’s Thoughts Into Nearly Instant Speech Using Artificial Intelligence

“This is where we are right now,” Edward Chang, a study co-author and neurosurgeon at UC San Francisco, says to the publication. “But you can imagine, with more sensors, with more precision, and with enhanced signal processing, those things are only going to change and get better.”

Montara Therapeutics Closes $20M Oversubscribed Seed Expansion, Appoints Troy Wilson as Chairman of the Board

Montara Therapeutics, a biotech company pioneering brain-selective therapies for CNS diseases, today announced the closing of a $20 million oversubscribed expansion of its Series Seed financing.